Immune Checkpoint Inhibitors: Clinical Trial Tracker

Immune Checkpoint Inhibitors: Clinical Trial Tracker

Oncology market, for decades, has been pillared on three areas: Surgery, Radiation Therapy and Chemotherapy. Immuno-oncology, especially immune checkpoint inhibitors, has recently gained traction from several stakeholders. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 inhibitor) was the first immune checkpoint inhibitor that was made commercially available in 2011 for treatment of patients suffering from unresectable or metastatic melanoma; it has enjoyed considerable success so far with annual sales of over USD 1 billion. The drug is currently being mirrored by various other drugs such as Opdivo, Keytruda, Empliciti and Tecentriq in clinical development.

The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. The field has been abuzz with partnering activities; such collaborations provide a synergistic boom to both the partners in terms of enrichment of product portfolio, revenues and stability. Most common forms of partnerships include clinical trial collaborations, product licensing agreements, acquisitions and research collaborations.

In addition to the marketed drugs, we expect a number of drugs currently in advanced stages of development to achieve blockbuster status in the near future. The anticipated success of immune checkpoint inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

The primary objective of this report is to capture details on the various clinical trials that are currently underway in the field of immune checkpoint inhibitors. We have identified a number of immune checkpoint inhibitors and clinical trials that are either being conducted or planned to be conducted for each of these drugs. For each specific product, we have provided the following information:
1. Primary Drug
2. Highest Phase of Development
3. Manufacturer / Licensee
4. Target Receptor
5. Molecule Type
6. Route of Administration

For each specific trial, we have provided the following information:
1. Indication
2. Therapeutic Area
3. Type of Cancer
4. Sponsor/Collaborator
5. Trial Title
6. Trial Objective
7. Trial Phase
8. Trial Status
9. Start Date
10. End Date
11. Enrolment
12. Age Group
13. Age Range
14. Gender
15. Inclusion Criteria
16. Exclusion Criteria
17. Study Type
18. Study Design
19. Primary Endpoints
20. Secondary Endpoints
21. Other Endpoints
22. Treatment Arm(s)
23. Location(s)
24. Primary Trial Identifier
25. Other Identifiers
26. Trial Results (if known)

The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.

In addition to the clinical trial details, the report also provides the following:
 Drivers and Restraints of the specific drug classes (CTLA-4 inhibitors, PD-1 / PDL-1 inhibitors and novel immune checkpoint inhibitors), wherein we have presented our opinion on the drivers and challenges associated with each of the drug class type.
 Sales forecast of the immune checkpoint inhibitors market over the course of next ten years. Owing to the emerging nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.

The data presented in this report has been gathered via secondary research. The prime secondary sources of information include
 Clinical trial registries
 Annual reports
 Investor presentations
 SEC filings
 Company websites
 Conference websites
 Industry analysts’ views

The focus has been on capturing the details on completed and ongoing clinical trials for immune checkpoint inhibitors. The report also provides an in-depth analysis of the competitive landscape for both pipeline molecules and clinical trials. The analysis is solely based on our knowledge and research gathered from various secondary sources of information.

1. Aarhus University Hospital
2. Abbott
3. AbbVie
4. Academic and Community Cancer Research United
5. Acerta Pharma BV
6. Acetylon Pharmaceuticals
7. ACT Oncology
8. Adknoma Health Research
9. Aduro BioTech
10. Advaxis
11. Affimed
12. Agenus
13. AgonOx
14. AHS Cancer Control Alberta
15. AIO-Studien-gGmbH
16. Alden Cancer Therapy II
17. Alliance Foundation Trials
18. Alligator Bioscience
19. Altor Bioscience
20. Ambrx
21. American Association for Cancer Research
22. Amgen
23. Amplimmune
24. AnaptysBio
25. Apexigen
26. arGEN-X
27. ARMO BioSciences
28. Astex Pharmaceuticals
29. AstraZeneca
30. Aurigene
31. Australasian Lung Cancer Trials Group
32. Australia and New Zealand Melanoma Trials Group
33. Australian and New Zealand Urogenital and Prostate Cancer Trials Group
34. Avon Breast Cancer Foundation
35. Azienda Ospedaliera Universitaria Senese
36. Bank of Cyprus Oncology Centre
37. Barbara Ann Karmanos Cancer Institute
38. Bayer
39. Baylor College of Medicine
40. BeiGene
41. BioInvent
42. Bio-Matrix Scientific Group
43. BioNovion
44. Boston Biomedical
45. Bristol-Myers Squibb
46. Brown University
47. California Pacific Medical Center Research Institute
48. Calithera Biosciences
49. Canadian Cancer Trials Group
50. Cancer Prevention Research Institute of Texas
51. Cancer Research Institute New York City
52. Cancer Research UK
53. Case Comprehensive Cancer Center
54. Cedars-Sinai Medical Center
55. Celgene
56. Cell Genesys
57. Celldex Therapeutics
58. Cellerant Therapeutics
59. Center for Cell and Gene Therapy Baylor College of Medicine
60. Central and Eastern European Oncology Group
61. Centre hospitalier de l'Université de Montréal
62. Centre Hospitalier Universitaire de Nice
63. Centre Hospitalier Universitaire Vaudois
64. Checkmate Pharmaceuticals
65. Checkpoint Therapeutics
66. Children's Hospital Los Angeles
67. City of Hope Medical Center
68. Clinica Universidad de Navarra
69. Cliniques universitaires Saint-Luc- Université Catholique de Louvain
70. Clovis Oncology
71. Columbia University
72. Comprehensive Cancer Center of Wake Forest University
73. Comprehensive Cancer Centers of Nevada
74. Compugen
75. Copenhagen University Hospital at Herlev
76. Corvus Pharmaceuticals
77. Cure Brain Cancer Foundation
78. CureTech
79. Curis
80. Dana-Farber Cancer Institute
81. Delcath Systems
82. Dendreon
83. Department of Experimental Clinical Oncology
84. Duke Cancer Institute
85. Duke University
86. Dutch Society of Physicians for Pulmonology and Tuberculosis
87. Dynavax Technologies
88. Earle A. Chiles Research Institute
89. Eastern Cooperative Oncology Group
90. Eddingpharm
91. Eisai
92. Eli Lilly and Company
93. EMD Serono
94. Emory University
95. Enumeral
96. EpicentRx
97. European CanCer Organisation
98. European Organisation for Research and Treatment of Cancer
99. European Thoracic Oncology Platform
100. Experimental Cancer Medicine Centre Network
101. Facet Biotech
102. Ferring Pharmaceuticals
103. Five Prime Therapeutics
104. Fondation ARC
105. Fondazione IRCCS Istituto Nazionale dei Tumori
106. Fondazione Melanoma Onlus
107. Fondazione Michelangelo
108. Fox Chase Cancer Center
109. Fred Hutchinson Cancer Research Center
110. Frontier Science Foundation
111. Galectin Therapeutics
112. Gateway for Cancer Research
113. Genentech
114. Georgetown University
115. Georgia Regents University
116. German Breast Group
117. GITR
118. GlaxoSmithKline
119. Gradalis
120. Groupe Oncologie Radiotherapie Tete et Cou
121. Grupo Español Multidisciplinar de Melanoma
122. H. Lee Moffitt Cancer Center and Research Institute
123. Hackensack University Medical Center
124. Hadassah Medical Organization
125. Halozyme Therapeutics
126. Haukeland University Hospital
127. Heat Biologics
128. Herlev Hospital
129. High Impact Clinical Research Support Program
130. Hoffmann-La Roche
131. HonorHealth Research Institute
132. Hoosier Cancer Research Network
133. Horizon Pharma Ireland
134. Hospices Civils de Lyon
135. Huntsman Cancer Institute
136. HUYA Bioscience International
137. Icahn School of Medicine at Mount Sinai
138. Idera Pharmaceuticals
139. Immune Design
140. ImmuNext
141. Immunocore
142. ImmunoVaccine Technologies
143. Immutep S.A.
144. INC Research
145. Incyte
146. Infinity Pharmaceuticals
147. Innate Pharma
148. Institut Bergonié
149. Institute of Cancer Research
150. Instituto Nacional de Cancerologia de Mexico
151. Intergroupe Francophone de Cancerologie Thoracique
152. International Breast Cancer Study Group
153. IOmet Pharma
154. ISA Pharmaceuticals
155. Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
156. Italian Network for Tumor Biotherapy Foundation
157. iTeos Therapeutics
158. James Graham Brown Cancer Center
159. Janssen Pharmaceuticals
160. Jewish General Hospital
161. Johns Hopkins University
162. Jonsson Comprehensive Cancer Center
163. Jounce Therapeutics
164. JSS Medical Research
165. Kadmon Corporation
166. KAHR Medical
167. Karyopharm Therapeutics
168. Kids' Cancer Research Foundation
169. King Faisal Specialist Hospital & Research Center
170. Korean Cancer Study Group
171. Kyowa Hakko Kirin Company
172. Ludwig Institute for Cancer Research
173. M.D. Anderson Cancer Center
174. MacroGenics
175. Mary Crowley Medical Research Center
176. Massachusetts General Hospital
177. Mayo Clinic
178. Medarex
179. Medical College of Wisconsin
180. Medical Research Council
181. Medical University of Vienna
182. MedImmune
183. Medivation
184. Melanoma Institute Australia
185. Melanoma Research Alliance
186. Memgen
187. Memorial Sloan Kettering Cancer Center
188. Merck KGaA
189. Merck Sharp & Dohme Corp.
190. Millennium Pharmaceuticals
191. Mologen AG
192. Multimeric Biotherapeutics
193. National Center for Tumor Diseases, Heidelberg
194. National Health and Medical Research Council, Australia
195. National Institute for Health Research, United Kingdom
196. National Institute of Allergy and Infectious Diseases
197. National Institutes of Health
198. Nativis
199. NCRI Clinical Studies Groups
200. New Mexico Cancer Care Alliance
201. New York University School of Medicine
202. NewLink Genetics
203. NHS Greater Glasgow and Clyde
204. Northside Hospital
205. Northwestern University
206. Norwegian Cancer Society
207. Norwegian Radium Hospital
208. Novartis
209. Ohio State University Comprehensive Cancer Center
210. OHSU Knight Cancer Institute
211. Oncolytics Biotech
212. OncoMed Pharmaceuticals
213. Oncothyreon
214. Oncovir
215. Ono Pharmaceutical
216. Optimata
217. Orega Biotech
218. Oregon Health and Science University
219. Oslo University Hospital
220. Ozmosis Research
221. Pelican Therapeutics
222. Peloton Therapeutics
223. Peregrine Pharmaceuticals
224. Peter MacCallum Cancer Centre
225. PETHEMA Foundation
226. Pfizer
227. Pharmaceutical Product Development
228. Pharmacyclics
229. Pieris Pharmaceuticals
230. Plexxikon
231. PRA Health Sciences
232. Prima BioMed
233. Prometheus Laboratories
234. Prostate Oncology Specialists
235. Provectus Pharmaceuticals
236. Providence Cancer Center
237. Providence Health & Services
238. PsiOxus Therapeutics
239. QuantumLeap Healthcare Collaborative
240. Queen Mary University of London
241. Queen's University, Belfast
242. Quintiles
243. Reata Pharmaceuticals
244. Regeneron Pharmaceuticals
245. Rhode Island Hospital
246. Robert H. Lurie Cancer Center
247. Roche / Genentech
248. Roswell Park Cancer Institute
249. Rouen University Hospital
250. Royal Marsden NHS Foundation Trust
251. RTOG Foundation
252. Rutgers Cancer Institute of New Jersey
253. Samsung Medical Center
254. Sanford Health
255. Sanofi
256. Sarcoma Alliance for Research through Collaboration
257. Seattle Genetics
258. Seoul National University Hospital
259. Servier
260. SGS Aster-Cephac
261. Sheba Medical Center
262. Sidney Kimmel Comprehensive Cancer Center
263. Solving Kids’ Cancer
264. Sorrento Therapeutics
265. Southern Illinois University
266. Southwest Oncology Group
267. Spanish Lung Cancer Group
268. St. Louis University
269. Stand Up To Cancer
270. Stanford University
271. Sunnybrook Health Sciences Centre
272. Swiss Group for Clinical Cancer Research
273. Syndax Pharmaceuticals
274. Takara Bio
275. Tapimmune
276. Tesaro
277. TetraLogic Pharmaceuticals
278. Texas Children's Hospital
279. TG Therapeutics
280. The EVAN Foundation
281. The First People's Hospital of Changzhou
282. The Leukemia and Lymphoma Society
283. The Methodist Hospital System
284. The Miriam Hospital
285. The Netherlands Cancer Institute
286. Theradex
287. Theravectys
288. Thomas Jefferson University
289. ToleroTech
290. Translational Genomics Research Institute
291. Transplant Genomics
292. U.S. Army Medical Research Acquisition Activity
293. Ultimovacs
294. Umanis
295. UNC Lineberger Comprehensive Cancer Center
297. United BioSource
298. United States Department of Defense
299. Universitair Ziekenhuis Brussel
300. University College London
301. University Health Network, Toronto
302. University Hospital Dresden
303. University Hospital Ghent
304. University Hospital Heidelberg
305. University Hospital Lille
306. University Hospital Southampton NHS Foundation Trust
307. University Hospital Tuebingen
308. University Medical Center Groningen
309. University of Birmingham
310. University of California
311. University of Chicago
312. University of Colorado Denver
313. University of Connecticut Health Center
314. University of Edinburgh
315. University of Glasgow
316. University of Heidelberg Medical Center
317. University of Leeds
318. University of Leicester
319. University of Louisville
320. University of Manchester
321. University of Michigan Cancer Center
322. University of Minnesota
323. University of Pennsylvania
324. University of Pittsburgh
325. University of Southampton
326. University of Southern California
327. University of Texas Southwestern Medical Center
328. University of Utah
329. University of Virginia
330. University of Washington
331. University of Wisconsin-Madison
332. University of Zurich
333. Vanderbilt University
334. Vanderbilt-Ingram Cancer Center
335. Vastra Gotaland Region
336. VentiRx Pharmaceuticals
337. Verastem
338. Viralytics
339. Vrije Universiteit Brussel
340. VU University Medical Center
341. Washington University School of Medicine
342. West Japan Oncology Group
343. Western Regional Medical Center
344. Yale University

Introduction and Pipeline Details
1. Market Overview
2. Dashboard: Pipeline and Trial Analysis
3. CTLA-4 Inhibitors: Trial Details
4. PD-1 Inhibitors: Trial Details
5. PDL-1 Inhibitors: Trial Details
6. Novel Immune Checkpoint Inhibitors: Trial Details
7. Molecules in Preclinical Development
8. Inclusion / Exclusion Criteria
9. Drivers and Restraints
10. Market Forecast: Assumptions
11. Market Forecast, 2016-2025
Pipeline and Trial Details
Figure 1 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Highest Phase of Development
Figure 2 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Target
Figure 3 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Phase of Development and Companies
Figure 4 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Type of Molecule
Figure 5 Immune Checkpoint Inhibitors in Clinical Development: Distribution by Key Players
Figure 6 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Trial Phase
Figure 7 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Trial Status
Figure 8 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Sponsor Type
Figure 9 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Tumor Type
Figure 10 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Study Type
Figure 11 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Gender Type
Figure 12 Immune Checkpoint Inhibitors Clinical Trials: Distribution by Molecule Type and Target
Figure 13 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Allocation Type
Figure 14 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Endpoint Classification
Figure 15 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Interventional Model
Figure 16 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Observational Model
Figure 17 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Masking
Figure 18 Immune Checkpoint Inhibitors Clinical Trials Design: Distribution by Primary Purpose
Figure 19 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by Continent
Figure 20 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by G7 Countries
Figure 21 Immune Checkpoint Inhibitors Clinical Trial Locations: Distribution by EU5 Countries
Figure 22 Immune Checkpoint Inhibitors in Preclinical Development: Distribution by Companies
Drivers and Restraints
Figure A: CTLA-4 Inhibitors: Drivers and Restraints
Figure B: PD-1 and PD-L1 Inhibitors: Drivers and Restraints
Figure C: Novel Immune Checkpoint Inhibitors: Drivers and Restraints
Market Forecast Analysis
Figure A: Immune Checkpoint Inhibitors Market Forecast, 2016-2025
Pipeline Analysis
Table A Companies Involved in the Development of Preclinical Immune Checkpoint Inhibitors
Pipeline Details
Table 1 CTLA-4 Inhibitors Clinical Development: Pipeline Details
Table 2 PD-1 Inhibitors Clinical Development: Pipeline Details
Table 3 PDL-1 Inhibitors Clinical Development: Pipeline Details
Table 4 Novel Immune Checkpoint Inhibitors Clinical Development: Pipeline Details
Table 5 Preclinical Development
Market Forecast Analysis
Table A Market Forecast: Assumptions

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook